Matsoukas, John ORCID: 0000-0001-5554-2964, Deraos, George, Kelaidonis, Kostas, Hossain, Md Kamal, Feehan, Jack ORCID: 0000-0002-9627-1299, Tzakos, AG ORCID: 0000-0001-6391-0288, Matsoukas, Elizabeth, Topoglidis, E ORCID: 0000-0002-0009-9309 and Apostolopoulos, Vasso ORCID: 0000-0001-6788-2771 (2021) Myelin peptide–mannan conjugate multiple sclerosis vaccines: conjugation efficacy and stability of vaccine ingredient. Vaccines, 9 (12). ISSN 2076-393X

Abstract

Myelin peptide–mannan conjugates have been shown to be potential vaccines in the immunotherapy of multiple sclerosis. The conjugates are comprised from the epitope peptide and the polysaccharide mannan which transfers as a carrier the antigenic peptide to dendritic cells that process and present antigenic peptides at their surface in complex with MHC class I or class II resulting in T-cell stimulation. The conjugation of antigenic peptide with mannan occurs through the linker (Lys–Gly)5, which connects the peptide with the oxidized mannose units of mannan. This study describes novel methods for the quantification of the vaccine ingredient peptide within the conjugate, a prerequisite for approval of clinical trials in the pursuit of multiple sclerosis therapeutics. Myelin peptides, such as MOG35–55, MBP83–99, and PLP131–145 in linear or cyclic form, as altered peptide ligands or conjugated to appropriate carriers, possess immunomodulatory properties in experimental models and are potential candidates for clinical trials.

Search Google Scholar

Repository staff login